Comments on: management of proliferative diabetic retinopathy.
Khorrami
Ali M
AM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007211:Indoles; D008301:Maleimides; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D007211:Indoles; D008301:Maleimides; D000068258:Bevacizumab; C099154:ruboxistaurin; D011493:Protein Kinase C; D014222:Triamcinolone Acetonide